(Albany, USA) DelveInsight’s “Chronic Insomnia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Insomnia, historical and forecasted epidemiology as well as the Chronic Insomnia market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Chronic Insomnia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Insomnia Market Forecast
Some of the key facts of the Chronic Insomnia Market Report:
- The Chronic Insomnia market size was valued approximately USD 333 Million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- In the 7 MM countries, there will be 5,697,127 cases of chronic insomnia that have been diagnosed as of 2021
- Age plays a significant role in how the disease develops. The age group of 20 to 29 years saw the highest number of cases in the US in 2021 with 474,746. Following this, there were 421,996 instances in the US for each of the age groups of 30-39 and 40-49 years
- Germany reported 207,625 instances of chronic insomnia in females and 199,483 cases in men among the EU5 nations in 2021
- Key Chronic Insomnia Companies: Vanda Pharmaceuticals, Janssen Pharmaceutical, Taisho Pharmaceutical, Neurim Pharmaceuticals, Imbrium Therapeutics, Defined Research, and others
- Key Chronic Insomnia Therapies: HETLIOZ (tasimelteon), Seltorexant (JNJ-42847922), Vornorexant (TS-142), Piromelatine (Neu-P11), Sunobinop (IMB-115), Defined CBD (cannabidiol), and others
- The Chronic Insomnia epidemiology based on gender analyzed that Chronic Insomnia is more prominent in females in comparison to males
- The Chronic Insomnia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Insomnia pipeline products will significantly revolutionize the Chronic Insomnia market dynamics.
Chronic Insomnia Overview
The most prevalent sleep condition, insomnia, has significant socioeconomic implications. Insomnia is defined by difficulty initiating, sustaining, or improving the quality of sleep, according to the International Classification of Sleep Disorders, third edition (ICSD-3). Despite having sufficient opportunity and conditions for sleep, these symptoms persist and cause malfunction during the day.
Get a Free sample for the Chronic Insomnia Market Report https://www.delveinsight.com/report-store/chronic-insomnia-market
Chronic Insomnia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Chronic Insomnia Epidemiology Segmentation:
The Chronic Insomnia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Chronic Insomnia
- Prevalent Cases of Chronic Insomnia by severity
- Gender-specific Prevalence of Chronic Insomnia
- Diagnosed Cases of Episodic and Chronic Chronic Insomnia
Download the report to understand which factors are driving Chronic Insomnia epidemiology trends @ Chronic Insomnia Epidemiology Forecast
Chronic Insomnia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Insomnia market or expected to get launched during the study period. The analysis covers Chronic Insomnia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Insomnia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Chronic Insomnia Therapies and Key Companies
- HETLIOZ (tasimelteon): Vanda Pharmaceuticals
- Seltorexant (JNJ-42847922): Janssen Pharmaceutical
- Vornorexant (TS-142): Taisho Pharmaceutical
- Piromelatine (Neu-P11): Neurim Pharmaceuticals
- Sunobinop (IMB-115): Imbrium Therapeutics
- Defined CBD (cannabidiol): Defined Research
Discover more about therapies set to grab major Chronic Insomnia market share @ Chronic Insomnia Treatment Market
Chronic Insomnia Market Drivers
- Increasing Prevalence
- Personalization of therapies
Chronic Insomnia Market Barriers
- Issues with diagnosis and poor knowledge
- Use of off-label drugs
- High economic burden
Scope of the Chronic Insomnia Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Chronic Insomnia Companies: Vanda Pharmaceuticals, Janssen Pharmaceutical, Taisho Pharmaceutical, Neurim Pharmaceuticals, Imbrium Therapeutics, Defined Research, and others
- Key Chronic Insomnia Therapies: HETLIOZ (tasimelteon), Seltorexant (JNJ-42847922), Vornorexant (TS-142), Piromelatine (Neu-P11), Sunobinop (IMB-115), Defined CBD (cannabidiol), and others
- Chronic Insomnia Therapeutic Assessment: Chronic Insomnia current marketed and Chronic Insomnia emerging therapies
- Chronic Insomnia Market Dynamics: Chronic Insomnia market drivers and Chronic Insomnia market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Chronic Insomnia Unmet Needs, KOL’s views, Analyst’s views, Chronic Insomnia Market Access and Reimbursement
To know more about Chronic Insomnia companies working in the treatment market, visit @ Chronic Insomnia Clinical Trials and Therapeutic Assessment
Table of Contents
1. Chronic Insomnia Market Report Introduction
2. Executive Summary for Chronic Insomnia
3. SWOT analysis of Chronic Insomnia
4. Chronic Insomnia Patient Share (%) Overview at a Glance
5. Chronic Insomnia Market Overview at a Glance
6. Chronic Insomnia Disease Background and Overview
7. Chronic Insomnia Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Insomnia
9. Chronic Insomnia Current Treatment and Medical Practices
10. Chronic Insomnia Unmet Needs
11. Chronic Insomnia Emerging Therapies
12. Chronic Insomnia Market Outlook
13. Country-Wise Chronic Insomnia Market Analysis (2019–2032)
14. Chronic Insomnia Market Access and Reimbursement of Therapies
15. Chronic Insomnia Market Drivers
16. Chronic Insomnia Market Barriers
17. Chronic Insomnia Appendix
18. Chronic Insomnia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting-services